2018 / 06

Next Paper
DOI: 10.24075/brsmu.2018.092

OPINION

Development of liposomal drug formulations: quality attributes and methods for quality control

Melnikova EV, Goryachev DV, Chaplenko AA, Vodyakova MA, Sayfutdinova AR, Merkulov VA
About authors

Scientific center for expert evaluation of medicinal products of the Ministry of health of the Russian Federation, Moscow

Correspondence should be addressed: Alexander A. Chaplenko
Shchukinskaya, 6 bl. 1, Moscow, 127051; ur.dempxe@oknelpahc

Received: 2018-06-29 Accepted: 2018-09-02 Published online: 2018-12-31
|
  1. Krasnopolsky YuM, Stepanov AE, Shvets VI. Technological aspects of production of liposomal preparations under GMP conditions. Biofarm J. 2009; 3: 18–29.
  2. Baryshnikov AYu. Nanostructured liposomal systems as a means of delivery of anticancer drugs. Vestnik RAMS. 2012; 3: 23–31.
  3. Hobbs SK, Monsky WL, Yuan F. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998; 95: 4607–4612.
  4. Shvets IV, Kaplun AP, Krasnopolsky YuM. et al. From liposome seventies to nanobiotechnology XXI century. Ross nanotechnologies. 2008; 3 (11–12): 6–20.
  5. Love WG, Amos N, Kellaway IW, Williams BD. Specific accumulation of cholesterol-rich liposomes in the inflammatory tissue of rats with adjuvant arthritis. Ann Rheum Dis. 1990; 49 (8): 611–614.
  6. Chekhonin VP, Baklaushev VP, Yusubalieva GM. et al. Modeling and immunohistochemical analysis of glioma C6. Cell technol in biol and med. 2007; 2: 65–73.
  7. Chekhonin VP, Zhirkov YuA, Gurina OI. et al. The Pegylated immunoliposome specific to astrocytes. Dokl. RAN. 2003; 391 (6): 1–7.
  8. Chekhonin VP, Gurina OI, Dmitrieva TB. Monoclonal antibodies to neurospecific proteins. M.: Medicine, 2007; 344.
  9. Errede M, Benagiano V, Girolamo F et al. Differential expression of connexin43 in foetal, adult and tumour-associated human brain endothelial cells. Histochem J. 2002; 34: 265–271.
  10. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale and clinical applications, existing and potential. Int J Nanomedicine. 2006; 1 (3): 297–315.
  11. Felnerova D, Viret J-F, Gluck R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004; 15: 518–529.
  12. Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci. 2001; 6: 66–77.
  13. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in drug targeting: opportunities and challenges. Curr Nanoscience. 2005; 1 (1): 47–64.
  14. Basu MK. Liposomal delivery of antileishmanial agents. J Applied Research. 2005; 5 (1): 221–236.
  15. Zurbriggen R, Amacker M, Krammer AR. Immunopotentiating reconstituted influenza virosomes. In: G. Gregoriadis eds. Liposome technology. 3rd edn. Vol. I. Liposome preparation and related techniques. New York: Informa Healthcare USA, 2007; 85–96.
  16. Fang J, Sawa T, Maeda H. Factors and mechanism of «epr» effect and the enhanced antitumor effects of macromolecular drugs including smancs. Adv Exp Med Biol. 2003; 519: 29–49.
  17. Greish K, Fang J, Inutsuka T. et al. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet. 2003; 42: 1089–1105.
  18. Maeda H. The enhanced permeability and retention (epr) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41: 189–207.
  19. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and Original Investigations. 2008; 26: 57–64.
  20. Lantsova AV. Creation and biopharmaceutical study of liposomal dosage forms of anticancer drugs derived from nitrosourea. Abstract dis kand farm. sciences. Moscow, 2006; 173.
  21. Lantsova AV, Oborotova NA, Peretolchina NM et al. Comparative study of the antitumor activity of the liposomal dosage forms of drugs, derivatives of nitrozomocevina. Sibirs oncologist J. 2005; 2 (14): 25–29.
  22. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002; 2 (10): 750–763.
  23. Tolcheva EV. Design of immunoliposomes and study of immunoliposomal form of anticancer drug doxorubicin. Abstract dis kand Biol sciences. M., 2007; 109 р.
  24. Sokolova DV, Tazina EV, Kortava MA. et al. Anti-CD40 and anti- HLA-DR immunoliposomal form doxorubicin: technology of production and antigen specificity in vivo. Ross biotherapeutic J. 2010; 9 (2): 90.
  25. Sokolova DV, Tazina EV, Kortava MA et al. Anti-MUC1 immunoliposomal form of doxorubicin: technology of production and antigen specificity in vitro. Ross biotherapeutic J. 2010; 9 (3): 21.
  26. Khugaeva OV, Kortava MA, Sokolova DV et al. Receiving liposomal mitoxantrone/materials of the IX all-Russian. scientific.- prakt. Conf. "Domestic anticancer drugs". Ross biotherapeutic J. 2010; 9 (2): 91.
  27. Nasonov EL. Prospects of rituximab use in autoimmune diseases of a person. Rus Med J. 2007; 15 (26): 1–6.
  28. Sokolova DV. Immunoliposomal constructions of doxorubicin and models for their preclinical study. Abstract dis kand Biol sciences. M., 2011; 122.
  29. Kawakami S, Fumoto S, Nishikawa M et al. In vivo gene delivery to the liver using novel galactosylated cationic liposomes. Pharmaceuttic Research. 2000; 17 (3): 306–313.
  30. Dass CR, Choong PFM. Targeting of small molecule anticancer drugs to the tumor and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int. 2006; 6 (17): 1–9.
  31. Ponce AM, Wright A, Dewhirst MW, Needham D. Targeted bioavailability of drugs by triggered release from liposomes. Future Lipidol. 2006; 1 (1): 25–34.
  32. Jain S, Mishra V, Singh P et al. RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm. 2003; 261 (1–2): 43–55.
  33. Qin J, Chen D, Hu H et al. Surface modification of RGD-liposomes for selective drug delivery to monocytes/Neutrophils in brain. Chem Pharm Bull. 2007; 55 (8): 1192–1197.
  34. Campbell RB, Fukumura D, Brown EB et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002; 62: 6831–6836.
  35. Ambegia E, Ansell S, Cullis P et al. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta. 2005; 1669 (2): 155–163.
  36. Dass CR. Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumor vasculature. Int J Pharm. 2003; 267 (1–2): 1–12.
  37. Tazina EV, Mescheryakova VV, Ignatieva EV et al. Biopharmaceutical studies of temperature-sensitive liposomal formulations of doxorubicin. Ross biotherapeutic J. 2009; 1 (8): 40–47.
  38. Huang Z, Szoka FC. Bioresponsive liposomes and their use for macromolecular delivery. In: G. Gregoriadis eds. Liposome technology. 3rd edn. Vol. I. Liposome preparation and related techniques. New York: Informa Healthcare USA, 2007; 165–196.
  39. Chekhonin VP, Zhirkov YuA, Aglow NV et al. Directed transport of drugs using liposomes. Vestn RAMS. 2004; 5: 42–47.
  40. Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci USA. 1999; 96: 254–259.
  41. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA. 2000; 97 (13): 7567–7572.
  42. Pal A, Ahmad A, Khan S et al. Systemic delivery of RafsiRNA using cationic liposomes silences Raf in xenograft model of human prostate cancer. Int J Oncol. 2005; 26 (4): 1087–1091.
  43. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray. Curr Drug Del. 2005; 2 (4): 429–441.
  44. Oliveira S, Storm G, Schiffelers. Targeted delivery of siRNA. J Biomed Biotechnol. 2006; 2006: 1–7.
  45. Miyazaki M, Obata Y, Abe K et al. Gene transfer using nonviral delivery systems. Perit Dial Int. 2006; 26: 633–640.
  46. Aguilar JC. Vaccine adjuvants revisited. Vaccine. 2007; 25: 3752– 3762.
  47. Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine. 2001; 19: 3301–3310.
  48. Pharmaceutical development: concept and practical recommendations. Scientific-practical guide for the pharmaceutical industry / ed. by Bykov SN, Vasilenko IA, Demina NB, Shokhin IE, Novojilov OV, Meshkovsky AP, Spitskov ORM. Pero, 2015; 472 р.
  49. Lu D, Hickey AJ. Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS Pharm Sci Tech. 2005; 6 (4): 641–648.
  50. De Lima MCP, Simoes S, Pires P et al. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Del Rev. 2001; 47: 277–294.